NCT07907354
Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Objective Response Rate (ORR)
Timeframe: every 2 cycles (each cycle is 21 or 28 days depending on chosen chemotherapy), up to disease progression or 24 months
Secondary (5)
Progression-Free Survival
Time to Progression (TTP)
Overall Survival (OS)
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Clinical Benefit Rate (CBR)
Arms and interventions
Apatinib + Physician's Choice ChemotherapyExperimental
Low-dose apatinib mesylate (250 mg orally once daily) combined with physician's choice single-agent chemotherapy (TPC). TPC is selected by investigator based on prior therapy, with XLD (capecitabine, vinorelbine, taxane, etc.) as priority. Treatment continues until disease progression or unacceptable toxicity.
Drugs: Apatinib mesylate, Physician's choice chemotherapy